The final word on the efficacy and safety of the CETP inhibitor class will await results from ongoing studies by Merck & Co. Inc. and Eli Lilly & Co. now that published data from Roche’s failed trial of dalcetrapib suggest there still could be hope for this class of HDL cholesterol-raising drugs.
Roche announced the termination of dalcetrapib’s development in May after an independent data safety and monitoring board advised discontinuation of the 15,800-patient dal-OUTCOMES study due to a lack of clinically meaningful efficacy Also see "